Published in Vasc Health Risk Manag on January 01, 2008
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
Safety of statins. Indian J Endocrinol Metab (2013) 1.08
Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol (2009) 1.04
Multi-ethnic analysis of lipid-associated loci: the NHLBI CARe project. PLoS One (2012) 0.98
Clinical and research applications of carotid intima-media thickness. Am J Cardiol (2009) 0.94
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool. Ther Clin Risk Manag (2013) 0.93
Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol (2012) 0.87
Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circ Res (2016) 0.81
Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012. Clin Cardiol (2016) 0.80
Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. Drug Des Devel Ther (2015) 0.76
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia. Pharmacogenet Genomics (2016) 0.76
Atorvastatin ameliorates myocardial ischemia/reperfusion injury through attenuation of endoplasmic reticulum stress-induced apoptosis. Int J Clin Exp Med (2014) 0.76
Pas de Deux: Glucagon and Thyroid Hormone Moving in Perfect Synchrony. Circ Res (2017) 0.75
Behind-the-counter statins: a silver bullet for reducing costs and increasing access? Health Serv Res (2011) 0.75
Potential drug interactions with statins: Estonian register-based study. Open Med (Wars) (2015) 0.75
Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br J Clin Pharmacol (2017) 0.75
Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth (2016) 0.75
Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian Heart J (2016) 0.75
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag (2017) 0.75
Intra-Arterial Drug and Light Delivery for Photodynamic Therapy Using Visudyne®: Implication for Atherosclerotic Plaque Treatment. Front Physiol (2016) 0.75
Screening for hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma (2017) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol (1998) 6.48
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol (2007) 4.93
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet (2003) 4.19
The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med (2000) 3.93
Structural mechanism for statin inhibition of HMG-CoA reductase. Science (2001) 3.45
Statin safety: a systematic review. Am J Cardiol (2006) 3.14
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation (2002) 3.05
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol (2005) 2.67
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation (2005) 2.19
An assessment of statin safety by muscle experts. Am J Cardiol (2006) 2.16
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol (2005) 2.11
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 2.07
Statin safety: an overview and assessment of the data--2005. Am J Cardiol (2006) 1.91
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol (2005) 1.71
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol (2003) 1.41
Update on statins: 2003. Circulation (2004) 1.37
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J (2004) 1.24
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J (2002) 1.21
Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry (2005) 1.20
The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf (2006) 1.20
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol (2007) 1.19
Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol (1999) 1.14
Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol (2006) 1.11
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J (2002) 1.11
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation (2007) 1.10
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol (2007) 1.10
Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care (2006) 1.08
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol (2003) 1.07
Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther (2004) 0.99
The issue of statin safety: where do we stand? Circulation (2005) 0.93
An assessment of statin safety by nephrologists. Am J Cardiol (2006) 0.93
Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care (2006) 0.92
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol (1994) 0.92
Rosuvastatin: an independent analysis of risks and benefits. MedGenMed (2006) 0.91
Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf (2006) 0.89
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol (2006) 0.88
Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy (2006) 0.88
The origin of the statins. 2004. Atheroscler Suppl (2004) 0.88
Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans (2003) 0.83
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs (2007) 0.82
Statin use in heart failure: a cause for concern? Am Heart J (2006) 0.79
Can a potent statin actually regress coronary atherosclerosis? JAMA (2006) 0.78
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther (2007) 0.77
A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Int J Clin Pract Suppl (2004) 0.77
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell (2012) 4.49
Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell (2013) 4.05
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Programming human pluripotent stem cells into white and brown adipocytes. Nat Cell Biol (2012) 2.26
Two ZBP1 KH domains facilitate beta-actin mRNA localization, granule formation, and cytoskeletal attachment. J Cell Biol (2002) 2.20
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs. Cell Stem Cell (2012) 1.72
Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest (2012) 1.71
Defining the spectrum of alleles that contribute to blood lipid concentrations in humans. Curr Opin Lipidol (2008) 1.59
A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet (2009) 1.36
The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem (2008) 1.25
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest (2014) 1.13
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation (2010) 1.07
Effect of patient visualization of coronary calcium by electron beam computed tomography on changes in beneficial lifestyle behaviors. Am J Cardiol (2008) 1.01
Protein-RNA and protein-protein recognition by dual KH1/2 domains of the neuronal splicing factor Nova-1. Structure (2011) 1.01
Gene-centric meta-analysis of lipid traits in African, East Asian and Hispanic populations. PLoS One (2012) 0.99
Clinical and research applications of carotid intima-media thickness. Am J Cardiol (2009) 0.94
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet (2015) 0.93
Treatment of an anterior communicating artery aneurysm through an anomalous anastomosis from the cavernous internal carotid artery. J Neurosurg (2002) 0.86
Genome-Edited Human Pluripotent Stem Cell-Derived Macrophages as a Model of Reverse Cholesterol Transport-Brief Report. Arterioscler Thromb Vasc Biol (2015) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Translating research into therapies. Cell (2012) 0.81
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet (2016) 0.80
Biomarkers for prediction of cardiovascular events. N Engl J Med (2007) 0.80
Functional evaluation of genetic variation in complex human traits. Hum Mol Genet (2012) 0.77
Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past, Present, and Future of Gene Expression Analysis. Front Genet (2013) 0.76
The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet (2017) 0.76
The Stroke Genetics Network: living up to its potential. Stroke (2013) 0.75
Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association. Circ Genom Precis Med (2020) 0.75
Top advances in functional genomics and translational biology for 2012. Circ Cardiovasc Genet (2013) 0.75
The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles. Clin Cardiol (2008) 0.75
Reply: Loss-of-Function Mutations to Estimate Pharmacological ANGPTL3 Inhibition. J Am Coll Cardiol (2017) 0.75
Top advances in functional genomics and translational biology for 2011. Circ Cardiovasc Genet (2012) 0.75